HC Wainwright Issues Pessimistic Forecast for SXTP Earnings

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) – Equities researchers at HC Wainwright lowered their Q4 2024 earnings per share estimates for 60 Degrees Pharmaceuticals in a research report issued on Tuesday, February 25th. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($4.77) per share for the quarter, down from their prior estimate of ($4.75). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($5.09) per share. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ FY2025 earnings at ($3.59) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Wednesday, February 19th.

60 Degrees Pharmaceuticals Stock Down 3.7 %

NASDAQ SXTP opened at $1.81 on Thursday. The company has a market cap of $2.67 million, a price-to-earnings ratio of -0.18 and a beta of 4.22. 60 Degrees Pharmaceuticals has a 52 week low of $1.78 and a 52 week high of $35.99. The business has a 50 day moving average price of $4.31 and a 200-day moving average price of $5.50.

Insider Activity

In other news, CEO Geoffrey S. Dow acquired 7,164 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was purchased at an average price of $6.35 per share, for a total transaction of $45,491.40. Following the completion of the acquisition, the chief executive officer now directly owns 18,916 shares in the company, valued at $120,116.60. The trade was a 60.96 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders bought a total of 12,073 shares of company stock worth $76,966 over the last quarter. 10.27% of the stock is currently owned by corporate insiders.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.